Orbis Medicines’ Post

View organization page for Orbis Medicines, graphic

1,196 followers

Today, we are thrilled to announce the official launch of Orbis Medicines alongside a €26 million financing. With our robust technology platform nGen, we can design orally bioavailable and membrane permeable macrocycle compounds – we think it’s a breakthrough and the start of a new era in #macrocycle #drugdevelopment after years of challenges in the design of macrocycle #medicines.   We were founded by the Seeds Investment team of Novo Holdings based on the scientific work of Prof. Christian Heinis and Sevan Habeshian at the Swiss Federal Institute of Technology in Lausanne (École polytechnique fédérale de Lausanne). Alongside Novo Holdings, European life sciences investment leader Forbion co-led the financing.   We look forward to transforming what is possible in the macrocycle space and ultimately delivering new therapeutic options to many #patients worldwide.   You can learn more about Orbis in our press release: https://lnkd.in/eP6PbUPc   #biotech

  • No alternative text description for this image

Congratulations, Orbis Medicines! We look forward to seeing more 🤩

Like
Reply

excellent news. Looking forward to knowing more about this new venture and how it can synergise with our ecosystem at Biopôle Lausanne

See more comments

To view or add a comment, sign in

Explore topics